Yamaguchi Junji, Gamble Mary V, Conlon Donna, Liang Jun-shan, Ginsberg Henry N
Department of Medicine, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA.
J Biol Chem. 2003 Oct 24;278(43):42643-51. doi: 10.1074/jbc.M306920200. Epub 2003 Aug 12.
The site where bulk lipid is added to apoB100 low density lipoproteins (LDL)/high density lipoproteins (HDL) particles to form triglyceride-enriched very low density lipoproteins (VLDL) has not been identified definitively. We employed several strategies to address this question. First, McA RH7777 cells were pulse-labeled for 20 min with [35S]methionine/cysteine and chased for 1 h (Chase I) to allow study of newly synthesized apoB100 LDL/HDL remaining in the endoplasmic reticulum (ER). After Chase I, cells were incubated for another hour (C2) with/without brefeldin A (BFA) and nocodazole (Noc) (to block ER to Golgi trafficking) and with/without oleic acid (OA). OA treatment alone during C2 increased VLDL secretion. This was prevented by the addition of BFA/Noc in C2. When C2 media were replaced by control media for another 1-h chase (C3), VLDL formed during OA treatment in C2 were secreted into C3 medium. Thus, OA-induced conversion of apoB100 LDL/HDL to VLDL during C2 occurred in the ER. Next, newly synthesized apoB100 lipoproteins were trapped in the Golgi by treatment with Noc and monensin during Chase I (C1), and C2 was carried out in the presence of BFA/Noc with/without OA and without monensin. Under these conditions, OA treatment during C2 did not stimulate VLDL secretion. The same pulse/chase protocols were followed by iodixanol subcellular fractionation, extraction of lipoproteins from ER and Golgi, and sucrose gradient separation of extracted lipoproteins. Cells treated with BFA/Noc and OA in C2 had VLDL in the ER. In the absence of OA, only LDL/HDL were present in the ER. The density of Golgi lipoproteins in these cells was not affected by OA. Similar results were obtained when ER were immuno-isolated with anti-calnexin antibodies. In conclusion, apoB100 bulk lipidation, resulting in conversion of LDL/HDL to VLDL, can occur in the ER, but not in the Golgi, in McA RH7777 cells.
将大量脂质添加到载脂蛋白B100低密度脂蛋白(LDL)/高密度脂蛋白(HDL)颗粒中以形成富含甘油三酯的极低密度脂蛋白(VLDL)的具体位点尚未明确确定。我们采用了几种策略来解决这个问题。首先,用[35S]甲硫氨酸/半胱氨酸对McA RH7777细胞进行20分钟的脉冲标记,然后进行1小时的追踪(追踪I),以便研究内质网(ER)中残留的新合成的载脂蛋白B100 LDL/HDL。追踪I后,将细胞在有/无布雷菲德菌素A(BFA)和诺考达唑(Noc)(以阻断从ER到高尔基体的运输)以及有/无油酸(OA)的条件下再孵育1小时(C2)。在C2期间单独用OA处理可增加VLDL的分泌。在C2中添加BFA/Noc可阻止这种情况发生。当在另一个1小时的追踪(C3)中将C2培养基替换为对照培养基时,C2期间OA处理过程中形成的VLDL被分泌到C3培养基中。因此,在C2期间OA诱导的载脂蛋白B100 LDL/HDL向VLDL的转化发生在内质网中。接下来,在追踪I(C1)期间用Noc和莫能菌素处理将新合成的载脂蛋白B100脂蛋白捕获在高尔基体中,并且在有BFA/Noc、有/无OA且无莫能菌素的情况下进行C2。在这些条件下,C2期间的OA处理不会刺激VLDL的分泌。通过碘克沙醇亚细胞分级分离、从ER和高尔基体中提取脂蛋白以及对提取的脂蛋白进行蔗糖梯度分离,遵循相同的脉冲/追踪方案。在C2中用BFA/Noc和OA处理的细胞在内质网中有VLDL。在没有OA的情况下,内质网中仅存在LDL/HDL。这些细胞中高尔基体脂蛋白的密度不受OA的影响。当用抗钙联蛋白抗体对内质网进行免疫分离时也获得了类似的结果。总之,在McA RH7777细胞中,导致LDL/HDL转化为VLDL的载脂蛋白B100大量脂化可发生在内质网中,而不是高尔基体中。